## Andreas Bechdolf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9477518/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. European Neuropsychopharmacology, 2022, 54, 90-99.	0.7	5
2	Specialized inpatient treatment for young people with early psychosis: acute-treatment and 12-month results. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1-14.	3.2	5
3	A comprehensive meta-analysis of the self-serving bias in schizophrenia spectrum disorders compared to non-clinical subjects. Neuroscience and Biobehavioral Reviews, 2021, 120, 542-549.	6.1	6
4	Implementation, efficacy, costs and processes of inpatient equivalent home-treatment in German mental health care (AKtiV): protocol of a mixed-method, participatory, quasi-experimental trial. BMC Psychiatry, 2021, 21, 173.	2.6	17
5	Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clinical Psychology Review, 2021, 86, 102005.	11.4	52
6	Individuals at increased risk for development of bipolar disorder display structural alterations similar to people with manifest disease. Translational Psychiatry, 2021, 11, 485.	4.8	13
7	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
8	Cognitive behavioral therapy in adolescents with early-onset psychosis: a randomized controlled pilot study. European Child and Adolescent Psychiatry, 2020, 29, 1011-1022.	4.7	11
9	Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 501-511.	3.2	8
10	Evidence for preventive treatments in young patients at clinical high risk of psychosis: the need for context. Lancet Psychiatry,the, 2020, 7, 378-380.	7.4	9
11	What is good mental health? A scoping review. European Neuropsychopharmacology, 2020, 31, 33-46.	0.7	131
12	The relationship between cannabis use and cognition in people diagnosed with first-episode psychosis. Psychiatry Research, 2020, 293, 113424.	3.3	8
13	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 41, 28-39.	0.7	56
14	Implementation of a Global Treatment Budget in Psychiatric Departments in Germany—Results and Critical Factors for Success From the Staff Perspective. Frontiers in Psychiatry, 2020, 11, 610.	2.6	5
15	Implementation of Guidelines on Prevention of Coercion and Violence (PreVCo) in Psychiatry: Study Protocol of a Randomized Controlled Trial (RCT). Frontiers in Psychiatry, 2020, 11, 579176.	2.6	13
16	Problems in measuring the JTC-bias in patients with psychotic disorders with the fish task: a secondary analysis of a baseline assessment of a randomized controlled trial. BMC Psychiatry, 2020, 20, 554.	2.6	11
17	Temporal dynamics of suspiciousness and hallucinations in clinical high risk and first episode psychosis. Psychiatry Research, 2020, 290, 113039.	3.3	15
18	Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action. European Neuropsychopharmacology, 2020, 36, 121-136.	0.7	17

#	Article	IF	CITATIONS
19	Efficacy of cognitiveâ€behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. Bipolar Disorders, 2020, 22, 517-529.	1.9	14
20	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	11.0	287
21	Theory of mind, emotion recognition, delusions and the quality of the therapeutic relationship in patients with psychosis – a secondary analysis of a randomized-controlled therapy trial. BMC Psychiatry, 2020, 20, 59.	2.6	6
22	Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). International Journal of Bipolar Disorders, 2020, 8, 22.	2.2	18
23	Früherkennung und Frühbehandlung von Menschen mit erhöhtem Psychoserisiko. , 2020, , 1-25.		Ο
24	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.7	38
25	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.9	71
26	Preventing and Reducing Coercive Measures—An Evaluation of the Implementation of the Safewards Model in Two Locked Wards in Germany. Frontiers in Psychiatry, 2019, 10, 340.	2.6	39
27	Creativity in persons atâ€risk for bipolar disorder—A pilot study. Microbial Biotechnology, 2019, 13, 1165-1172.	1.7	10
28	Predictors of treatment response to psychological interventions in people at clinical high risk of firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 120-127.	1.7	5
29	Negative schemata about the self and others and paranoid ideation in atâ€risk states and those with persisting positive symptoms. Microbial Biotechnology, 2018, 12, 1157-1165.	1.7	6
30	Evaluation of Flexible and Integrative Psychiatric Treatment Models in Germany—A Mixed-Method Patient and Staff-Oriented Exploratory Study. Frontiers in Psychiatry, 2018, 9, 785.	2.6	24
31	Clinical high risk for psychosis: gender differences in symptoms and social functioning. Microbial Biotechnology, 2017, 11, 306-313.	1.7	54
32	Coping and the stages of psychosis: an investigation into the coping styles in people at risk of psychosis, in people with firstâ€episode and multipleâ€episode psychoses. Microbial Biotechnology, 2017, 11, 147-155.	1.7	18
33	Ethical considerations in preventive interventions for bipolar disorder. Microbial Biotechnology, 2017, 11, 104-112.	1.7	12
34	Bipolar At-Risk Criteria: An Examination of Which Clinical Features Have Optimal Utility for Identifying Youth at Risk of Early Transition From Depression to Bipolar Disorders. Schizophrenia Bulletin, 2017, 43, 737-744.	4.3	42
35	Prevalence of metabolic syndrome in female and male patients at risk of psychosis. Schizophrenia Research, 2017, 181, 38-42.	2.0	34
36	Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Microbial Biotechnology, 2016, 10, 17-27.	1.7	19

ANDREAS BECHDOLF

#	Article	IF	CITATIONS
37	Temperament and prodromal symptoms prior to first manic/hypomanic episodes: Results from a pilot study. Journal of Affective Disorders, 2015, 173, 39-44.	4.1	21
38	Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. Journal of Affective Disorders, 2015, 183, 45-48.	4.1	33
39	Why Do Bad Things Happen to Me? Attributional Style, Depressed Mood, and Persecutory Delusions in Patients With Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1338-1346.	4.3	46
40	Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk participants. Schizophrenia Research, 2014, 153, 25-31.	2.0	51
41	Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 17-25.	3.2	17
42	The predictive validity of bipolar atâ€risk (prodromal) criteria in helpâ€seeking adolescents and young adults: a prospective study. Bipolar Disorders, 2014, 16, 493-504.	1.9	103
43	Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12month and longer-term follow-ups. Schizophrenia Research, 2013, 149, 56-62.	2.0	333
44	The bipolar disorder prodrome revisited: Is there a symptomatic pattern?. Journal of Affective Disorders, 2013, 151, 551-560.	4.1	34
45	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.0	1,222
46	Basic Symptoms and the Prediction of First-Episode Psychosis. Current Pharmaceutical Design, 2012, 18, 351-357.	1.9	152
46 47		1.9 1.8	152 46
	351-357. Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging		
47	<ul> <li>351-357.</li> <li>Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2012, 201, 34-39.</li> <li>Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy,</li> </ul>	1.8	46
47 48	<ul> <li>351-357.</li> <li>Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2012, 201, 34-39.</li> <li>Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis. Schizophrenia Bulletin, 2011, 37, S111-S121.</li> <li>A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking</li> </ul>	1.8 4.3	46 69
47 48 49	<ul> <li>351-357.</li> <li>Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2012, 201, 34-39.</li> <li>Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis. Schizophrenia Bulletin, 2011, 37, S111-S121.</li> <li>A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. Journal of Affective Disorders, 2010, 127, 316-320.</li> <li>Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical</li> </ul>	1.8 4.3 4.1	46 69 104
47 48 49 50	<ul> <li>351-357.</li> <li>Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2012, 201, 34-39.</li> <li>Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis. Schizophrenia Bulletin, 2011, 37, S111-S121.</li> <li>A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. Journal of Affective Disorders, 2010, 127, 316-320.</li> <li>Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials, 2010, 11, 123.</li> <li>Randomized Comparison of Group Cognitive Behaviour Therapy and Croup Psychoeducation in Acute Patients with Schizophrenia: Effects on Subjective Quality of Life. Australian and New Zealand Journal</li> </ul>	1.8 4.3 4.1 1.6	46 69 104 26
47 48 49 50 51	<ul> <li>351-357.</li> <li>Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2012, 201, 34-39.</li> <li>Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis. Schizophrenia Bulletin, 2011, 37, S111-S121.</li> <li>A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. Journal of Affective Disorders, 2010, 127, 316-320.</li> <li>Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials, 2010, 11, 123.</li> <li>Randomized Comparison of Group Cognitive Behaviour Therapy and Group Psychoeducation in Acute Patients with Schizophrenia: Effects on Subjective Quality of Life. Australian and New Zealand Journal of Psychiatry, 2010, 44, 144-150.</li> <li>Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial</li> </ul>	1.8 4.3 4.1 1.6 2.3	<ul> <li>46</li> <li>69</li> <li>104</li> <li>26</li> <li>44</li> </ul>

#	Article	IF	CITATIONS
55	Cognitive-behavioral therapy in the pre-psychotic phase: An exploratory study. Psychiatry Research, 2005, 136, 251-255.	3.3	57
56	Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 2005, 79, 137-143.	2.0	90
57	Determinants of subjective quality of life in post acute patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 228-235.	3.2	84
58	The Concept of Schizophrenia and Phase-Specific Treatment: Cognitive-Behavioral Treatment in Pre-Psychosis and in Nonresponders. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 2003, 31, 209-228.	0.3	23
59	Self-experienced vulnerability, prodromal symptoms and coping strategies preceding schizophrenic and depressive relapses. European Psychiatry, 2002, 17, 384-393.	0.2	43
60	Cognitive Behavioral Therapy for Psychosis (CBTp): Multicenter Randomized Clinical Trial on Specific Efficacy. SSRN Electronic Journal, 0, , .	0.4	2